Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
The primary objective of the study is to determine the safety and tolerability of multiple doses of orally administered EDP-788. Secondary objectives of the study are to describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after multiple doses of orally administered drug.
Key facts
- Study ID
- NCT02255968
- Run by
- Enanta Pharmaceuticals, Inc
- People needed
- 16
- Starts
- 2014-08-01
- Expected to finish
- 2014-10-01
- Last updated by the study team
- 2015-05-12
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- PPD Phase 1 Clinic — Austin, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.